Evidence map›Paper›PMID 34536148›Full record

ArticleArchivum immunologiae et therapiae experimentalis2021

Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition.

Morvarid Siri, Hamid Behrouj, Sanaz Dastghaib, Mozhdeh Zamani, Wirginia Likus, Sedigheh Rezaie, Jacek Hudecki, Saeed Khazayel, Marek J Łos, Pooneh Mokarram and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Archivum immunologiae et therapiae experimentalis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 38 citations in OpenAlex.

  1. Targeting CDK2 and AURKA with Cerevisterol fromInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Morvarid SiriAutophagy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hamid BehroujDepartment of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, P.O Box: 1167, Shiraz, Iran.
Sanaz DastghaibDepartment of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, P.O Box: 1167, Shiraz, Iran.
Mozhdeh ZamaniAutophagy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Wirginia LikusDepartment of Anatomy, School of Health Science in Katowice, Medical University of Silesia, ul. Medyków 18, 40-762, Katowice, Poland.ORCID http://orcid.org/0000-0002-4738-6102
Sedigheh RezaieDepartment of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, P.O Box: 1167, Shiraz, Iran.
Jacek HudeckiLaryngology Department, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.ORCID http://orcid.org/0000-0002-2876-9087
Saeed KhazayelDepartment of Research and Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Marek J ŁosAutophagy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. mjelos@gmail.com.ORCID http://orcid.org/0000-0001-9518-1411
Pooneh MokarramAutophagy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. mokaram2@gmail.com.ORCID http://orcid.org/0000-0002-9717-0473
Saeid GhavamiAutophagy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. saeid.ghavami@umanitoba.ca.ORCID http://orcid.org/0000-0001-5948-508X
Shiraz University of Medical Sciences · IRMedical University of Silesia · PLKermanshah University of Medical Sciences · IR

Funding

national institute for medical research and development 943267shiraz university of medical science 97-01-01-18115
6 · The paper itself

Abstract

Adjuvant chemotherapy with 5-fluorouracil (5-FU) does not improve survival of patients suffering from a form of colorectal cancer (CRC) characterized by high level of microsatellite instability (MSI-H). Given the importance of autophagy and multi-drug-resistant (MDR) proteins in chemotherapy resistance, as well as the role of casein kinase 1-alpha (CK1α) in the regulation of autophagy, we tested the combined effect of 5-FU and CK1α inhibitor (D4476) on HCT116 cells as a model of MSI-H colorectal cancer. To achieve this goal, the gene expression of Beclin1 and MDR genes, ABCG2 and ABCC3 were analyzed using quantitative real-time polymerase chain reaction. We used immunoblotting to measure autophagy flux (LC3, p62) and flow cytometry to detect apoptosis. Our findings showed that combination treatment with 5-FU and D4476 inhibited autophagy flux. Moreover, 5-FU and D4476 combination therapy induced G2, S and G1 phase arrests and it depleted mRNA of both cell proliferation-related genes and MDR-related genes (ABCG2, cyclin D1 and c-myc). Hence, our data indicates that targeting of CK1α may increase the sensitivity of HCT116 cells to 5-FU. To our knowledge, this is the first description of sensitization of CRC cells to 5-FU chemotherapy by CK1α inhibitor.

Indexed as

Casein Kinase IalphaColorectal NeoplasmsApoptosisCell Line, TumorDrug Resistance, NeoplasmFluorouracilHumansMicrosatellite InstabilityMicrosatellite RepeatsCasein Kinase IalphaFluorouracil5-FluorouracilAutophagyCasein kinase 1 alpha inhibitorChemoresistanceColorectal cancerCombination treatment

Identifiers

PMID34536148
PMCPMC8449776
OpenAlexW3199690095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.